Conflict of interest: the authors declare that they have no conflicts of interest.
Clinical dermatology ● Concise report
Refractory pyoderma gangrenosum treated with infliximab in an infant
Article first published online: 18 MAR 2014
© 2014 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 39, Issue 3, pages 336–339, April 2014
How to Cite
Campos-Muñoz, L., Conde-Taboada, A., Aleo, E., Toledano, E. and López-Bran, E. (2014), Refractory pyoderma gangrenosum treated with infliximab in an infant. Clinical and Experimental Dermatology, 39: 336–339. doi: 10.1111/ced.12297
- Issue published online: 18 MAR 2014
- Article first published online: 18 MAR 2014
- Manuscript Accepted: 20 NOV 2013
We report the case of an 11-month-old boy with severe recalcitrant pyoderma gangrenosum refractory to prednisone, dapsone and ciclosporin. Treatment with infliximab was well tolerated, and resulted in an excellent clinical response that has been sustained for 15 months. The characteristics of this condition in children and the use of infliximab in infants are both reviewed.